Medical Diagnostic Laboratories LLC (MDL), Hamilton, NJ, is a CLIA-certified infectious disease laboratory specializing in high-complexity, state-of-the-art, automated, DNA-based molecular analyses. By using molecular techniques, MDL is able to provide clinicians from many different specialties with valuable information to assist them in the diagnosis, evaluation, and treatment of viral, fungal, and bacterial infections.
Femeris Women’s Health Research Center™, an MDL institute, was established to translate women’s health research into diagnostic tests. This new Aerobic Vaginitis (AV) Panel by PCR, available through MDL, will provide another tool for clinicians to accurately diagnosis diseases associated with abnormal levels of vaginal flora, thereby facilitating proper treatment regimens to achieve an effective cure.
AV is caused by the overgrowth of aerobic pathogens such as Escherichia coli, Group B streptococcus, staphylococcus aureus, and enterococcus faecalis that trigger a localized vaginal inflammatory immune response as evidenced by clinical signs and symptoms, including the presence of vaginal discharge, an elevation of the vaginal pH, inflammation with leukocyte infiltration, and a marked depletion of healthy lactobacillus species. There are important distinctions between AV and bacterial vaginosis (BV). Unlike AV, BV is a common vaginal disorder associated with the overgrowth of anaerobic bacteria and a distinct vaginal, malodorous discharge, but is not usually associated with a strong vaginal inflammatory immune response. BV is traditionally treated with metronidazole therapy that targets anaerobic bacteria. However, approximately 20% of women diagnosed with BV and treated with metronidazole will fail to respond to therapy and will experience a recurrence of symptoms. Often these patients are misdiagnosed and actually suffer from AV, which requires an antibiotic therapy against the aerobic bacteria. AV has been implicated in complications of pregnancy such as ascending chorioamnionitis, premature rupture of the membranes and preterm delivery.
"This test offering is another example of MDL’s efforts to provide tailored, molecular diagnostic approaches to address polymicrobial-based, chronic, persistent, and complex diseases," says Eli Mordechai, PhD, CEO. Recently, the company introduced another test for BV that offers lactobacillus profiling analysis, at no additional charge. The new AV test provides physicians with valuable data that is essential for a patient’s stratification, therapy, and prognosis, he adds.
"MDL’s selective molecular testing platforms are specifically designed to address chronic diseases well beyond the identification of a specific pathogen," Mordechai says, "Such advances as demonstrated by many other tests currently offered by MDL are possible by extending traditional detection assays to include molecular antimicrobial resistance profiles and genetic surrogate markers."